Chisholm Peter, Brown Jared, Jiranantakan Thanjira, Harrod Mary Ellen, McDonald Catherine, Cullinan Una, Roberts Darren M
Centre for Alcohol and Other Drugs, New South Wales Ministry of Health, Sydney, New South Wales, Australia.
New South Wales Poisons Information Centre, Sydney Children's Hospitals Network, Sydney, New South Wales, Australia.
Emerg Med Australas. 2025 Apr;37(2):e70038. doi: 10.1111/1742-6723.70038.
Recent years have seen sporadic reports in Australia of stimulants being contaminated with opioids. Since late 2023, there has been an increase in opioid overdoses among individuals in New South Wales (NSW) using substances believed to be cocaine or methamphetamine. We analysed the frequency and characteristics of these cases and describe our public health responses.
The Prescription, Recreational & Illicit Substance Evaluation (PRISE), operated by NSW health since July 2018, is a statewide surveillance, epidemiology, and toxicity response programme. We did a retrospective analysis of each case of opioid toxicity following use of cocaine or methamphetamine submitted to the PRISE programme from January 2022 to June 2024, categorising cases into confirmed, probable, and suspected.
Thirty-four cases were found, 19 involving cocaine and 15 involving methamphetamine. Twenty-two (65%) were classified as confirmed, and 12 (35%) as probable. There were two deaths (6%). Twenty-three cases (68%) were in Sydney. Multiple stakeholders reviewed trends and formulated public health responses, leading to the distribution of public drug warnings and media releases in November 2023 and February 2024 because of ongoing case detections.
The increase in detections, which continued in the months following the public health responses, underscores the need for comprehensive surveillance, response, monitoring, and reporting of this phenomenon in NSW. Engagement with clinicians and the community is essential for the success of this programme.
近年来,澳大利亚有关于兴奋剂被阿片类药物污染的零星报道。自2023年末以来,新南威尔士州(NSW)使用疑似可卡因或甲基苯丙胺的物质的人群中阿片类药物过量情况有所增加。我们分析了这些病例的发生频率和特征,并描述了我们的公共卫生应对措施。
自2018年7月起由新南威尔士州卫生部运营的处方、娱乐及非法药物评估(PRISE)项目,是一个全州范围的监测、流行病学及毒性应对项目。我们对2022年1月至2024年6月提交至PRISE项目的使用可卡因或甲基苯丙胺后出现阿片类药物毒性的每例病例进行了回顾性分析,将病例分为确诊、可能和疑似三类。
共发现34例病例,其中19例涉及可卡因,15例涉及甲基苯丙胺。22例(65%)被归类为确诊,12例(35%)为可能。有两例死亡(6%)。23例(68%)发生在悉尼。多个利益相关方审查了趋势并制定了公共卫生应对措施,由于持续有病例被发现,于2023年11月和2024年2月发布了公共药物警告和媒体声明。
在公共卫生应对措施实施后的几个月里,检测到的病例数仍在增加,这凸显了在新南威尔士州对这一现象进行全面监测、应对、监测和报告的必要性。与临床医生和社区的合作对于该项目的成功至关重要。